Document Type
Article
Publication Date
10-9-2014
Publication Title
BioMed Central Infectious Diseases
Department
Geisel School of Medicine
Abstract
Aminoglycosides are a critical component of multidrug-resistant tuberculosis (MDR-TB) treatment but data on their efficacy and adverse effects in Botswana is scarce. We determined the effect of amikacin on treatment outcomes and development of hearing loss in MDR-TB patients. Patients started on MDR-TB treatment between 2006 and 2012 were included. Multivariate analysis was used to determine the effect of amikacin on treatment outcomes and development of hearing loss.
DOI
10.1186/1471-2334-14-542
Dartmouth Digital Commons Citation
Modongo, Chawangwa; Sobota, Rafal S.; Kesenogile, Boikobo; and Ncube, Ronald, "Successful MDR-TB Treatment Regimens Including Amikacin are Associated with High Rates of Hearing Loss" (2014). Dartmouth Scholarship. 627.
https://digitalcommons.dartmouth.edu/facoa/627
Comments
Chawangwa Modongo;Rafal S Sobota;Boikobo Kesenogile;Ronald Ncube;Giorgio Sirugo;Scott M Williams;Nicola M Zetola